University of Ghent
Faculty of Pharmaceutical Sciences, Department of Pharmaceutics, Laboratory of General Biochemistry and Physical Pharmacy
The LGBPP, hosting both the Ghent Research Group on Nanomedicines (GRGN) and the Bio-photonic Imaging Group (BPIG), mainly performs pre-clinical research in the field of micro-and nanomaterials for biomedical applications. GRGN is largely involved in the design and evaluation of novel micro-and nanomaterials for drug delivery, therapy and diagnostics, whereas research of the BPIG is focused on the development of biophotonic methodologies for biomedical applications. More specifically, a major focus in the LGBPP is the development of novel strategies to improve delivery of nucleic acid therapeutics (siRNA, miRNA, mRNA, pDNA), representing a class of molecules which are not yet in clinical use though under intensive scrutiny for therapeutic applications. Besides on the design of such delivery materials (e.g. nanomedicines), LGBPP aims to unravel their biophysical behavior following administration, both in relevant extracellular fluids (e.g. full blood, lung sputa, gastric fluids, intraperitoneal fluids,…) as well as in the intracellular environment. To this end, the Ghent Group has developed a unique expertise in the application of advanced microscopy methods to measure nanoparticle stability in all sorts of biological fluids. In the coming years, exploring the delivery potential of nanomedicines for biotechnological drugs will remain the major research theme of our group. Therapeutic emphasis will be placed on (i) pulmonary delivery of nanomedicines (inflammatory/infectious diseases of the lung), (ii) intravitreal delivery of nanomedicines (retinal diseases), (iii) intraperitoneal administration of nanomedicines (cancer) and (iv) cancer immunotherapy. The LGBPP is an international and multidisciplinairy research group, containing about 30 persons and has many collaborations with academic groups worldwide.
ESR 8: Colloidaly stable nanogel formulations for pulmonary siRNA delivery
ESR 9: Colloidal stable liposomal formulations for in vivo siRNA delivery
ESR 14: Polycationic amphiphilic cyclodextrins (CDs) for intraperitoneal siRNA/PXT delivery